Literature DB >> 33248322

Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.

Giuseppe Giaccone1, Chul Kim2.   

Abstract

Here, we present an update of a phase 2 study of pembrolizumab in patients with advanced thymic carcinoma who failed previous therapies. Duration of response was approximately 3 years, and median survival was in excess of 2 years with a 5-year survival rate of 18%. The higher than expected incidence of severe autoimmune disorders (15%) did not substantially increase with a longer follow-up. Pembrolizumab induces durable responses in patients with thymic carcinoma. Careful selection of patients and monitoring of toxicities are warranted.
Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Pembrolizumab; Response; Survival; Thymic carcinoma

Mesh：

Substances：

Year:  2020        PMID： 33248322     DOI： 10.1016/j.jtho.2020.11.003

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  7 in total

1.  Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome.

Authors:  Giovanni Bocchialini; Ana-Iris Schiefer; Leonhard Müllauer; Jürgen Thanner; Jonas Bauer; Felizia Thaler; Maria Laggner; Cecilia Veraar; Walter Klepetko; Konrad Hötzenecker; José Ramon Matilla; Hendrik Jan Ankersmit; Bernhard Moser
Journal:  Br J Cancer       Date:  2022-06-24       Impact factor: 9.075

Review 2.  Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword.

Authors:  Madison Ballman; Chen Zhao; Meredith J McAdams; Arun Rajan
Journal:  Cancers (Basel)       Date:  2022-04-20       Impact factor: 6.575

3.  Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.

Authors:  Zhengbo Song; Guangyuan Lou; Yina Wang; Zhiping Yang; Wenxian Wang; Yongling Ji; Shiqing Chen; Chunwei Xu; Xiao Hu; Yiping Zhang
Journal:  BMC Med       Date:  2022-05-10       Impact factor: 8.775

4.  Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report.

Authors:  Yoichi Nishii; Kazuki Furuhashi; Kentaro Ito; Tadashi Sakaguchi; Yuta Suzuki; Kentaro Fujiwara; Taro Yasuma; Tetsu Kobayashi; Corina N D'Alessandro-Gabazza; Esteban C Gabazza; Osamu Taguchi; Osamu Hataji
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-19

5.  Distinguishing between thymic carcinoma and lung carcinoma: a medical oncologist's perspective.

Authors:  Arun Rajan; Cristina Mullenix; Meredith J McAdams
Journal:  Mediastinum       Date:  2022-09-25

6.  Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report.

Authors:  Cui Chen; Peng Sun; Jianting Long
Journal:  Front Immunol       Date:  2022-08-02       Impact factor: 8.786

Review 7.  Narrative review of immunotherapy in thymic malignancies.

Authors:  Jose Carlos Benitez; Benjamin Besse
Journal:  Transl Lung Cancer Res       Date:  2021-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.